Early palliative care for patients with advanced sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if early involvement of palliative care alongside standard treatment can enhance the quality of life for patients diagnosed with advanced or metastatic soft tissue sarcoma. Participants will complete quality of life questionnaires before starting treatment and every six weeks for a total of 24 weeks. The study will compare outcomes between those receiving standard treatment alone and those receiving both standard treatment and early palliative care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed written and voluntary informed consent.
* Have histologically documented advanced sarcoma, either locally advanced not amenable to curative treatment, or metastatic.
* Age ≥ 18 years.
* Have not received any previous systemic treatment with palliative intent for advanced sarcoma.
* Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
* Life expectancy \> 6 months.
* Willing/able to complete questionnaires.

Exclusion Criteria:

* Clinical evidence of cognitive impairment that would preclude the ability to provide informed consent and complete questionnaires, at investigator´s discretion.
* Patient in need of urgent home support services or symptom management through a palliative care team.
* Patient is being actively followed by a palliative care physician.
* Active psychiatric disorder or drug abuse.
* Insufficient English literacy to complete questionnaires.

Where it's running

• Mount Sinai Hospital
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Albiruni R. Abdul Razak — Mount Sinai Hospital
• Study coordinator: Clinical Trials Manager
• Email: Oncology.Research@sinaihealth.ca
• Phone: 416-586-8440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Fluorescence-guided surgery to reduce unexpected positive margins in high-grade sarcoma

  This phase II trial tests whether adding fluorescence-guided surgery with indocyanine green can lower unexpected positive margins in patients with high-grade sarcoma compared to standard surgery.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07650656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.